Skip to main content
. Author manuscript; available in PMC: 2021 Jan 2.
Published in final edited form as: Clin Cancer Res. 2020 Aug 14;26(20):5304–5309. doi: 10.1158/1078-0432.CCR-20-2272

Table 1. Common features of AML and MDS with TP53 aberrations.

TP53 aberrations in AML and MDS affect hematopoietic stem and progenitor cells
TP53 aberrations in AML and MDS contribute to genetic instability and are driver events of leukemogenesis
AML and MDS with TP53 mutations show
  • -

    gross chromosomal aberrations (-5/5q-, complex and monosomal karyotypes)

  • -

    a paucity of cooperating gene mutations

Patients with AML and MDS with TP53 aberrations are of older age
TP53 aberrations are frequent in therapy-related AML and MDS
TP53 aberrations constitute adverse risk parameters in patients with AML and MDS
Following intensive treatments, patients with AML and MDS with TP53 aberrations show
  • -

    low complete remission rates

  • -

    increased relapse rates

  • -

    inferior OS

Following nonintensive treatments, patients with AML and MDS with TP53 aberrations show
  • -

    shorter remission duration

  • -

    inferior OS

Note: “Intensive treatments” include chemotherapy ± allogeneic hematopoietic stem cell transplantation; “nonintensive treatments” refer to hypomethylating agents (azacitidine and decitabine) ± BCL2 inhibition (venetoclax).